Document Detail


Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
MedLine Citation:
PMID:  18600079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The period between isolation of HIV in the early 1980s and the development of effective viral inactivation procedures able to eradicate the virus from the blood supply was long and unfortunately many recipients of blood-derived products became infected; this translated into a devastating impact on their quality of life, quality of care as well as on their life expectancy. Some years later, hepatitis C virus infection was identified as another known blood-borne disease complicating the treatment of haemophilia. Nowadays, the potential threat of emerging new pathogens has stressed the need to provide effective but primarily safe products with regard to infectious agents, as well as to regularly update therapeutic guidelines for haemophilia. The aim of the present publication was to review some of the crucial aspects related to the choice of haemostatic concentrates for the treatment of haemophilia and other inherited bleeding disorders, to analyse the current situation in the United States, Canada and European Union countries and to report the most relevant aspects of the Spanish consensus opinion of haemophilia-treating doctors for the use of therapeutic products for haemophilia recently issued. Essentially, it suggests that a gradual switch to recombinant concentrates may be a beneficial decision for patients with haemophilia and for the National Health Service.
Authors:
Javier Batlle; Ana Villar; Antonio Liras; Concepción Alonso; Carmen Altisent; Dilia Brito; Manuel Moreno; Félix Lucía; Carmen Sedano; Manuel Prieto; Natividad Calvente; José A Aznar; Víctor Jiménez; Vicente Soriano; Javier R Martorell; Gemma Iruín; Juan M Bergua; Carlos Aguilar
Related Documents :
23091309 - Proportion of multidrug-resistant tuberculosis in human immunodeficiency virus/mycobact...
23018379 - Low-level hiv viremia is associated with microbial translocation and inflammation.
24018499 - Oral acetyl-l-carnitine treatment in hepatic encephalopathy: view of evidence-based med...
15321019 - Predictors of major depression in recently diagnosed patients with hiv/aids in south af...
24882169 - Dasabuvir: a non-nucleoside inhibitor of ns5b for the treatment of hepatitis c virus in...
23910059 - Severe chronic hepatitis secondary to prolonged use of ecstasy and cocaine.
18595129 - Is there a place for serum laminin determination in patients with liver disease and can...
16883439 - Indeterminate human immunodeficiency virus western blot results in iranian patients wit...
24256749 - Diffuse cerebral vasculopathy in a hiv-positive patient with recurrent strokes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  19     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-07     Completed Date:  2009-08-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  333-40     Citation Subset:  IM    
Affiliation:
Scientific Committee, Royal Foundation Victoria Eugenia, Madrid, Spain. jbattle@canalejo.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Component Transfusion*
Blood-Borne Pathogens
HIV
HIV Infections / prevention & control*,  transmission
Hemophilia A / therapy*
Hepatitis C / prevention & control*,  transmission
Practice Guidelines as Topic
Quality of Health Care
Quality of Life
Spain
Virus Inactivation*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protecting patients from harm: reducing methicillin-resistant Staphylococcus aureus infections.
Next Document:  The use of recombinant factor VIIa in liver diseases.